HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Compare relative returns, fundamentals, and sector rankings head-to-head.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Tempest Therapeutics

Contributing Author

Recent Articles by Tempest Therapeutics

Jun-04
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors TPST GlobeNewswire
May-29
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds TPST -11.56% GlobeNewswire
May-14
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update TPST +13.59% TPST -12.44% GlobeNewswire
May-06
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting TPST -6.05% GlobeNewswire
Apr-29
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting TPST GlobeNewswire
Apr-22
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T TPST GlobeNewswire
Apr-14
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts TPST +5.14% GlobeNewswire
Mar-30
Tempest Reports Year End 2025 Financial Results and Provides Business Update TPST -12.14% GlobeNewswire
Mar-23
Tempest Therapeutics Announces Up To $6 Million Private Placement TPST -19.65% GlobeNewswire
Mar-11
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 TPST GlobeNewswire
Feb-25
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 TPST -6.43% GlobeNewswire
Feb-11
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets TPST GlobeNewswire
Feb-04
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets TPST -6.30% TPST GlobeNewswire
Jan-20
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders TPST -5.15% GlobeNewswire
Nov-26
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST GlobeNewswire
Nov-25
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules TPST -23.26% GlobeNewswire
Nov-19
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 TPST -48.59% GlobeNewswire
Nov-05
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update TPST +9.10% GlobeNewswire
Aug-11
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update TPST +9.99% TPST +8.83% GlobeNewswire
Jun-30
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China TPST GlobeNewswire
Jun-11
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock TPST -15.88% GlobeNewswire
Jun-05
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC TPST +15.16% GlobeNewswire
May-13
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update TPST GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)